Search Result

18 search results for Histiocytic Neoplasms

NCCN Guidelines Histiocytic Neoplasms

NCCN Guidelines Histiocytic Neoplasms, NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms

https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

Erdheim-Chester Disease

NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms

https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

Langerhans Cell Histiocytosis

NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms

https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

Rosai-Dorfman Disease

NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms

https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

Permission to Cite or Use NCCN Content

Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi, Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Lung, Hematopoietic Growth Factors Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi, and Neck Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma

https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-content

Recently Updated Guidelines

Carcinoma Version 4.2024 Histiocytic Neoplasms Version 3.2024 Hodgkin Lymphoma

https://www.nccn.org/guidelines/recently-published-guidelines

Transparency Process

Histiocytic Neoplasms Panel, Version: 1.2023 ( Histiocytic Neoplasms ) Date: 2022-12-02 Transparency Panel Disclosures/Attendance Version: 1.2022 ( Histiocytic Neoplasms ) Date: 2021-12-16, Transparency Panel Disclosures/Attendance Version: 3.2024 ( Uterine Neoplasms ) Date, : 2.2024 ( Uterine Neoplasms ) Date: 2024-02-29 Transparency Panel Disclosures/Attendance

https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations

Treatment by Cancer Type

Version: 4.2024 Histiocytic Neoplasms Version, /Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version: 2.2024 Myeloproliferative Neoplasms, Carcinoma Version: 5.2024 Uterine Neoplasms

https://www.nccn.org/guidelines/category_1

Guidelines Panels

Cancers Panel Histiocytic Neoplasms, Myeloproliferative Neoplasms Panel

https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panels

Resume Screening

Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi, Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma, Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal Cancer Vulvar, Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms Nasopharyngeal Cancer

https://www.nccn.org/covid-19/resume-screening

Submission Request Form

Histiocytic Neoplasms - 3.2024 Hodgkin Lymphoma - 1.2025 Kaposi Sarcoma - 2.2025 Kidney Cancer, - 2.2025 Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions - 2.2024 Myeloproliferative Neoplasms - 2.2024 Neuroblastoma - 2.2024 Neuroendocrine and Adrenal Tumors, Thyroid Carcinoma - 5.2024 Uterine Neoplasms - 1.2025 Vaginal Cancer - 3.2025 Vulvar Cancer

https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-form

Current Opportunities

and Neck Cancers Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin, /Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms, Testicular Cancer Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal Cancer, Mouth Cancer Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms

https://www.nccn.org/education-research/nccn-oncology-research-program/current-opportunities

HIT

and Neck Cancers Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary, Lymphomas Testicular Cancer Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal, Mesothelioma Mouth Cancer Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms

https://www.nccn.org/redirects/hit

Guidelines With Evidence Blocks

Version 1.2025 Hepatocellular Carcinoma Version 4.2024 Histiocytic Neoplasms Version, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 2.2024 Myeloproliferative Neoplasms Version 2.2024 Neuroendocrine and Adrenal Tumors, Version 1.2024 Thyroid Carcinoma Version 4.2024 Uterine Neoplasms Version 1.2025

https://www.nccn.org/guidelines/guidelines-with-evidence-blocks

Chemotherapy Order Templates Reviewer Acknowledgement

Roswell Park Comprehensive Cancer Center Histiocytic Neoplasms, , BCOP Moffitt Cancer Center Myeloid/Lymphoid Neoplasms, Styler, MD Fox Chase Cancer Center Myeloproliferative Neoplasms, University of Michigan Rogel Cancer Center Uterine Neoplasms Emily

https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagement

Advocacy and Support Groups

Myeloproliferative Neoplasms Neuroendocrine Tumors Ovarian Cancer Pancreatic Cancer Prostate Cancer Rectal, Association is a global nonprofit organization supporting people impacted by all histiocytic, , raising awareness for all histiocytic disorders, and funding research that will lead us to cures, including histiocytic sarcoma, and diabetes inspidus (known as Arginine Vasopressin Deficiency or AVP

https://www.nccn.org/patientresources/patient-resources/resources-for-patients-caregivers/advocacy-and-support-groups

Submission Request History

Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020 Pembrolizumab, Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020 Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GlaxoSmithKline on 05/15/2020, for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020 Pembrolizumab, and TMB testing for Uterine Neoplasms Submitted by Foundation Medicine, Inc. on 06/30/2020

https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-history